Vitamin D as add on Therapy to Metformin and Teneligliptin in patients with type 2 Diabetes Mellitus

Abstract

A low level of vitamin D is being attributed to the development of diabetes, which can cause insulin resistance, beta-cell death, and inflammation. Vitamin D supplementation can reduce inflammation and insulin resistance. we conducted this study for our population to evaluate the effect of vitamin D on blood glucose in type 2 diabetes mellitus. A prospective interventional, parallel, randomized study, was conducted on 112 type two diabetes and 25(OH) D deficient patients. The control group received Metformin (500mg BD) and Teneligliptin (20mg OD) only, while the intervention group was given Metformin plus Teneligliptin along with vitamin D (Cholecalciferol) (60,000 IU). At the end of 3rd of month follow-up, there was a significant difference in mean FPG and PPG (129.86±7.36mg/dl) vs. (136.12±11.31mg/dl) (p=0.002), (220.81±13.04mg/dl) vs. (228.06±19.40 mg/dl) (p=0.037). in the interventional and control group respectively. And subsequently, mean HbA1c improved significantly in the interventional group as compared to the control group 7.21±0.40% vs. 7.48.0.62% respectively (p = 0.015). also, the measures of glycemic control (FPG, PPG, HbA1c) showed a significant improvement at the end of the 6 months. Our study suggested, that add-on therapy of Vitamin D improved the glycemic parameters of type two diabetes mellitus with concurrent vitamin D deficiency over the course of the study.